Quadruple-negative breast cancer: novel implications for a new disease

Breast Cancer Research

Geetanjali Saini¹  Shristi Bhattarai¹  Ritu Aneja¹  Keerthi Gogineni² 

[1] Department of Biology, Georgia State University;Department of Hematology and Medical Oncology, Emory University School of Medicine;

关键词: Quadruple-negative breast cancer;    Triple-negative breast cancer;    Androgen receptor;    AR antagonists;    Cancer biomarkers;    Therapeutic targets;   

DOI  :  10.1186/s13058-020-01369-5

来源: DOAJ

【 摘 要 】

Abstract Based on the androgen receptor (AR) expression, triple-negative breast cancer (TNBC) can be subdivided into AR-positive TNBC and AR-negative TNBC, also known as quadruple-negative breast cancer (QNBC). QNBC characterization and treatment is fraught with many challenges. In QNBC, there is a greater paucity of prognostic biomarkers and therapeutic targets than AR-positive TNBC. Although the prognostic role of AR in TNBC remains controversial, many studies revealed that a lack of AR expression confers a more aggressive disease course. Literature characterizing QNBC tumor biology and uncovering novel biomarkers for improved management of the disease remains scarce. In this comprehensive review, we summarize the current QNBC landscape and propose avenues for future research, suggesting potential biomarkers and therapeutic strategies that warrant investigation.

【 授权许可】

Unknown